ECSP10010160A - Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep) - Google Patents

Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)

Info

Publication number
ECSP10010160A
ECSP10010160A EC2010010160A ECSP10010160A ECSP10010160A EC SP10010160 A ECSP10010160 A EC SP10010160A EC 2010010160 A EC2010010160 A EC 2010010160A EC SP10010160 A ECSP10010160 A EC SP10010160A EC SP10010160 A ECSP10010160 A EC SP10010160A
Authority
EC
Ecuador
Prior art keywords
arb
nep
antagonist
super
inhibitor
Prior art date
Application number
EC2010010160A
Other languages
English (en)
Inventor
Alan Edward Royce
Colleen Ruegger
Suliman Al-Fayoumi
Jiahui Hu
Natrajan Kumaraperumal
Erika Aina Zannou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010160(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP10010160A publication Critical patent/ECSP10010160A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las formas de dosificación oral sólidas, en especial tabletas, de una composición farmacéutica que comprende un complejo supramolecular, se pueden formar a partir de un proceso de compresión directa o de un proceso de compactación, tal como compactación con rodillos. Estas formas de dosificación oral sólida proporcionan un perfil de liberación inmediata que permite tener una rápida liberación del agente terapéutico. Un complejo supramolecular particularmente útil es el propionato-(S)-3'-metil-2'-(pentanoil-{2"-(tetrazol-5-ilato)-bifenil-4'-il-metil}-amino)-butirato]-hemipentahidrato de [3-((1S,3R)-1-bifenil-4-il-metil-3-etoxi-carbonil-1-butil-carbamoílo) de trisodio
EC2010010160A 2007-11-06 2010-05-06 Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep) ECSP10010160A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98566807P 2007-11-06 2007-11-06

Publications (1)

Publication Number Publication Date
ECSP10010160A true ECSP10010160A (es) 2010-06-29

Family

ID=40451030

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010160A ECSP10010160A (es) 2007-11-06 2010-05-06 Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)

Country Status (33)

Country Link
US (3) US20100267786A1 (es)
EP (4) EP2295035B1 (es)
JP (2) JP5653218B2 (es)
KR (2) KR101589317B1 (es)
CN (2) CN101848700A (es)
AR (1) AR069184A1 (es)
AU (1) AU2008324878B2 (es)
BR (1) BRPI0823505A2 (es)
CA (1) CA2703598C (es)
CL (1) CL2008003298A1 (es)
CY (2) CY1116280T1 (es)
DK (3) DK2217205T3 (es)
EC (1) ECSP10010160A (es)
ES (3) ES2587336T3 (es)
FI (1) FI3067043T3 (es)
GT (1) GT201000131A (es)
HR (3) HRP20150459T1 (es)
HU (2) HUE028866T2 (es)
IL (3) IL262990B2 (es)
JO (1) JOP20080499B1 (es)
MA (1) MA31797B1 (es)
MX (1) MX2010004930A (es)
MY (1) MY153730A (es)
NZ (1) NZ584686A (es)
PE (2) PE20141072A1 (es)
PL (3) PL2295035T3 (es)
PT (3) PT2295035T (es)
RU (1) RU2493844C3 (es)
SG (1) SG185951A1 (es)
SI (3) SI2295035T1 (es)
TN (1) TN2010000200A1 (es)
TW (1) TWI484982B (es)
WO (1) WO2009061713A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101848700A (zh) 2007-11-06 2010-09-29 诺瓦提斯公司 基于血管紧张素受体拮抗剂/阻断剂(arb)和中性内肽酶(nep)抑制剂的超结构的双重作用的药物组合物
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
SG176010A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
PH12013500231A1 (en) * 2010-08-24 2017-08-09 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
SI2887961T1 (sl) * 2012-08-24 2021-08-31 Novartis Ag Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju
NZ710574A (en) 2013-02-14 2017-11-24 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
WO2014126972A1 (en) 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
EP3038653A1 (en) * 2013-08-26 2016-07-06 Novartis AG New use
RS65037B1 (sr) 2013-08-26 2024-02-29 Novartis Ag Lečenje kardiovaskularnih oboljenja
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
PL3229799T3 (pl) 2014-12-08 2019-05-31 Crystal Pharmatech Co Ltd Krystaliczne postacie supramolekularnego kompleksu trisodowego zawierającego walsartan i AHU-377 i ich sposoby
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
HUE071910T2 (hu) 2015-05-11 2025-10-28 Novartis Ag Szakubitril-valzartán adagolási rend krónikus szisztolés szívelégtelenség kezelésére
EP3302460A1 (en) 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
CN106176724A (zh) * 2015-07-11 2016-12-07 凌莉 一种稳定的固体药物组合物及其制备方法
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106397249A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种高稳定性lcz696结晶粉末及其制备方法
WO2017037596A1 (en) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of lcz-696
JP6598985B2 (ja) 2015-08-28 2019-10-30 ノバルティス アーゲー 新規の使用
WO2017063581A1 (zh) * 2015-10-16 2017-04-20 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (en) * 2015-11-20 2017-05-26 Lupin Limited Amorphous sacubitril-valsartan complex and process for preparation thereof
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN105935358B (zh) * 2015-12-18 2019-06-07 重庆两江药物研发中心有限公司 一种沙库比曲缬沙坦缓释剂及其制备方法
CN105929031B (zh) * 2015-12-18 2018-08-21 重庆两江药物研发中心有限公司 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
US10722471B2 (en) 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
HRP20250913T1 (hr) * 2016-02-03 2025-09-26 Novartis Ag Nova upotreba kombinacije sakubitrila i valsartana
CN105748420B (zh) * 2016-03-04 2018-11-06 山东省药学科学院 一种治疗心力衰竭的lcz696缓释骨架片的制备方法
CN105902506A (zh) * 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种沙卡布曲缬沙坦制剂及其应用
WO2018069937A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof
EP3600255B1 (en) * 2017-03-31 2021-07-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Stable hot-melt extrudate containing valsartan and sacubitril
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2018211479A1 (en) * 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2019020706A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
US20200276129A1 (en) 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
WO2019180735A1 (en) * 2018-03-19 2019-09-26 Natco Pharma Limited Stable pharmaceutical compositions comprising sacubitril-valsartan complex
US11877576B2 (en) 2018-06-22 2024-01-23 Ideaz, Llc Diphenyl tablets and methods of preparing the same
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
KR102545274B1 (ko) 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20210138510A (ko) 2020-05-12 2021-11-19 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US607893A (en) 1898-07-26 Automatic switch-operating machine
US607355A (en) 1898-07-12 Carrier for bicycles
US608220A (en) 1898-08-02 Mechanical movement
US735093A (en) 1903-01-31 1903-08-04 Oscar Greenwald Elevator-cable guard.
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
PL340587A1 (en) * 1997-11-17 2001-02-12 Smithkline Beecham Corp Oral preparations of high therapeutic substance content with instantaneous or modifiable release of such substance and methods of obtaining them
WO1999065500A1 (en) * 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
KR100646716B1 (ko) 1998-12-23 2006-11-17 노파르티스 아게 Ａｔ-1 또는 ａｔ-2 수용체의 증가와 관련된 질환의치료에 있어서 ａｔ-1 수용체 길항제 또는 ａｔ-2 수용체조절제의 용도
BR0112665A (pt) 2000-07-19 2003-06-24 Novartis Ag Sais
PT1467728E (pt) 2002-01-17 2007-11-14 Novartis Ag Composições farmacêuticas compreendendo valsartan e inibidores da nep
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
WO2003089417A1 (en) 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1511739B1 (en) 2003-03-17 2008-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of valsartan
EP1648515B1 (en) * 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidone combinations
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
JP2009513622A (ja) * 2005-10-27 2009-04-02 ルピン・リミテッド ロサルタンの医薬製剤
WO2007052307A2 (en) 2005-10-31 2007-05-10 Lupin Limited Stable solid oral dosage forms of valsartan
EP1951111B1 (en) 2005-11-07 2010-08-11 Stryker Corporation Patient handling device including local status indication, one-touch fowler angle adjustment, and power-on alarm configuration
CA2626682A1 (en) 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
CN101848700A (zh) 2007-11-06 2010-09-29 诺瓦提斯公司 基于血管紧张素受体拮抗剂/阻断剂(arb)和中性内肽酶(nep)抑制剂的超结构的双重作用的药物组合物

Also Published As

Publication number Publication date
PE20091390A1 (es) 2009-10-13
JP5653218B2 (ja) 2015-01-14
HUE061321T2 (hu) 2023-06-28
HRP20150459T1 (hr) 2015-07-17
GT201000131A (es) 2012-04-30
ES2939163T3 (es) 2023-04-19
DK2217205T3 (en) 2015-05-11
NZ584686A (en) 2013-03-28
EP2295035A2 (en) 2011-03-16
US20100267786A1 (en) 2010-10-21
ES2587336T3 (es) 2016-10-24
EP4186491A1 (en) 2023-05-31
SG185951A1 (en) 2012-12-28
HK1143529A1 (en) 2011-01-07
DK3067043T3 (da) 2023-02-27
IL205208A (en) 2017-01-31
RU2493844C3 (ru) 2017-07-05
US20240115536A1 (en) 2024-04-11
BRPI0823505A2 (pt) 2015-06-16
US20210085631A1 (en) 2021-03-25
EP2295035A3 (en) 2012-08-08
PL2295035T3 (pl) 2016-11-30
EP2295035B1 (en) 2016-05-18
IL262990B1 (en) 2023-06-01
KR101700062B9 (ko) 2022-11-23
KR20100085087A (ko) 2010-07-28
TW200936183A (en) 2009-09-01
JP2011503082A (ja) 2011-01-27
DK2295035T3 (en) 2016-08-29
PT2217205E (pt) 2015-06-08
FI3067043T3 (fi) 2023-03-18
RU2493844C2 (ru) 2013-09-27
TN2010000200A1 (en) 2011-11-11
PE20141072A1 (es) 2014-09-10
KR101589317B9 (ko) 2022-11-23
SI3067043T1 (sl) 2023-04-28
MA31797B1 (fr) 2010-10-01
PL3067043T3 (pl) 2023-05-08
HRP20160988T1 (hr) 2016-10-07
AU2008324878A1 (en) 2009-05-14
EP2217205A1 (en) 2010-08-18
EP2217205B1 (en) 2015-03-04
CN103251587A (zh) 2013-08-21
PT3067043T (pt) 2023-03-01
IL262990A (en) 2018-12-31
AR069184A1 (es) 2010-01-06
EP3067043B1 (en) 2022-11-30
IL205208A0 (en) 2010-12-30
HRP20230178T3 (hr) 2023-03-31
CY1116280T1 (el) 2017-03-15
JP2015038069A (ja) 2015-02-26
TWI484982B (zh) 2015-05-21
CL2008003298A1 (es) 2009-06-26
AU2008324878B2 (en) 2013-04-18
ES2536514T3 (es) 2015-05-26
SI2295035T1 (sl) 2016-09-30
CA2703598A1 (en) 2009-05-14
PT2295035T (pt) 2016-08-22
CY1117883T1 (el) 2017-05-17
IL262990B2 (en) 2023-10-01
KR101589317B1 (ko) 2016-01-28
JOP20080499B1 (ar) 2022-09-15
HK1149721A1 (en) 2011-10-14
PL2217205T3 (pl) 2015-07-31
MX2010004930A (es) 2010-05-27
HUE028866T2 (en) 2017-01-30
EP3067043A1 (en) 2016-09-14
KR20150139624A (ko) 2015-12-11
SI2217205T1 (sl) 2015-10-30
WO2009061713A1 (en) 2009-05-14
MY153730A (en) 2015-03-13
CA2703598C (en) 2016-08-09
IL249922A0 (en) 2017-03-30
RU2010123027A (ru) 2011-12-20
HK1224195A1 (en) 2017-08-18
CN101848700A (zh) 2010-09-29
KR101700062B1 (ko) 2017-01-26

Similar Documents

Publication Publication Date Title
AR069184A1 (es) Una composicion farmaceutica que comprende una superestructura (lcz696), de un antagoniste/bloqueante (arb) del recptor angiotensina, e inhibidor de la endopeptidasa neutra (nep).
ES2526606T3 (es) Composición farmacéutica sólida que comprende amlodipina y losartán
PE20070420A1 (es) Formulacion que contiene una combinacion de valsartan y amlodipina
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
BR112012006346A2 (pt) agonista de receptor de acetilcolina, composto, composição farmacêutica, combinação e uso de ativadores de receptor de acetilcolina nicotínico alfa 7
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
CU23551B7 (es) Procedimiento para la producción de una composición farmacéutica sólida de administración oral
BRPI0915084B8 (pt) composto, e, composição farmacêutica
CR9875A (es) Inhibidores de dipeptidilo peptidasa para tratar diabetes
CO6362012A2 (es) Clohidarto de nalmefeno dihidratado
CO6400186A2 (es) Tabletas de acetato de ulipristal
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
PA8778101A1 (es) Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
MA37886A1 (fr) Nouvelles pyridinones bicycliques
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CL2007002899A1 (es) Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros.
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
UY32852A (es) [4-(5-aminometil-fenil)-piperidin-1-il]-1h-indol-3-il]-metanonas disustituidas.
CL2008003780A1 (es) Compuestos derivados de azetidinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento o la prevencion de trastornos psiquiatricos, dependencia o deshabituacion a una sustancia, trastornos cognitivos, enfermedades neurodegenerativas, entre otras.
CO6270299A2 (es) Composiciones farmaceuticas de accion doble basadas en super estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidores de endopeptidasa neutra (nep)
CL2009001005A1 (es) Compuestos derivados de butirato de trimetilamonio, inhibidores de cpt2; proceso de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de enfermedades tales como hiperglucemia, diabetes, hipertension, entre otras patologias.